Imatinib, also known as griseofulvin, is a novel protein tyrosine kinase inhibitor with the ability to block a variety of proteases. It is used clinically for the treatment of all stages of chronic myeloid leukemia and also for the treatment of CD117-positive gastrointestinal mesenchymal stromal cell tumors. Dosage: The recommended starting dose for acute and accelerated stages of chronic myeloid leukemia is 600 mg orally once daily, which may be increased to 400 mg orally twice daily if the disease continues to progress and the patient does not experience serious adverse reactions. If hematologic adverse reactions occur and the neutrophil count is less than 0.5×10^9/L or platelet count is less than 10×10^9/L, a dose reduction to 400 mg per day is recommended. if the hematocrit continues for 2 weeks, the dose should be further reduced to 300 mg per day. if the hematocrit continues for 4 weeks, treatment should be discontinued until the neutrophil count is above 1.0×10^9/L and the platelet The dose should be resumed after the neutrophils are above 20×10^9/L. In the chronic phase, the dose should be 400 mg orally once daily and may be increased to 600 mg daily if the disease continues to progress and the patient does not experience serious adverse effects. If the neutrophil count or platelet count decreases again, the dose should be reduced to 300 mg/day when the drug is resumed. The adverse effects of imatinib include gastrointestinal reactions such as nausea, vomiting, loss of appetite, diarrhea, etc. Neutropenia, thrombocytopenia, anemia, and neutropenic fever are common in the hematologic system. Neurological system commonly includes dizziness, headache, insomnia, and taste disorder. Other adverse reactions include generalized swelling, various rashes, dermatitis, muscle cramps, joint pain, etc.